FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1799863640> ?p ?o ?g. }

• W1799863640 abstract "Autologous stem cell transplantation is widely used to restore functioning bone marrow in people with malignant lymphoma or multiple myeloma after myeloablative chemotherapy. Results of some clinical trials indicate that plerixafor in addition to granulocyte colony-stimulating factors (G-CSF) compared to G-CSF only could lead to an increased mobilisation and release of CD34-positive cells, facilitating effective apheresis.To evaluate the efficacy and safety of additional plerixafor to G-CSF for haematopoietic stem cell mobilisation in people with malignant lymphoma or multiple myeloma.We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (from 1990 to September 2015), as well as conference proceedings (American Society of Hematology; American Society of Clinical Oncology; European Hematology Association; American Society for Blood and Marrow Transplantation; European Group for Blood and Marrow Transplantation) for studies. Two review authors independently screened search results.We included randomised controlled trials (RCTs) comparing plerixafor in addition to G-CSF compared to G-CSF only for stem cell mobilisation in people with malignant lymphoma or multiple myeloma of all stages and ages. We included full text as well as abstracts and unpublished data if sufficient information on study design, participant characteristics, interventions, and outcomes was available. We excluded cross-over trials, quasi-randomised trials, and post-hoc retrospective trials.Two review authors independently screened the results of the search strategies, extracted data, assessed quality, and analysed data according to standard Cochrane methods. We performed final interpretation with an experienced clinician.We identified four RCTs fitting the inclusion criteria. However, two of these closed prematurely due to low recruitment and did not report results. The remaining two trials evaluated 600 participants with multiple myeloma or non-Hodgkin lymphoma. In both studies the experimental group received G-CSF plus plerixafor and the control group received G-CSF plus placebo.The meta-analysis showed no evidence for differences between plerixafor and placebo group regarding mortality at 12 months (600 participants; risk ratio (RR) 1.00, 95% confidence interval (CI) 0.59 to 1.69; P = 1.00; moderate-quality evidence) and adverse events during stem cell mobilisation and collection (593 participants; RR 1.02, 95% CI 0.99 to 1.06; P = 0.19; high-quality evidence).Regarding the outcome successful stem cell collection, the meta-analysis showed an advantage for those participants randomised to the plerixafor group (600 participants; RR 2.42, 95% CI 1.98 to 2.96; P < 0.00001; high-quality evidence).As there was high heterogeneity between studies for the number of transplanted participants, we did not meta-analyse these data. In the multiple myeloma study, 95.9% (142 participants) in the plerixafor arm and 88.3% (136 participants) in the placebo arm underwent transplantation (RR 1.09, 95% CI 1.02 to 1.16); in the non-Hodgkin lymphoma trial, 90% (135 participants) in the plerixafor group versus 55.4% (82 participants) in the placebo group could be transplanted (RR 1.62, 95% CI 1.39 to 1.89). In both trials there was no evidence for a difference between participants in the plerixafor and placebo group in terms of time to neutrophil and platelet engraftment in transplanted participants.None of the trials reported on the outcomes quality of life and progression-free survival.The results of the analysed data suggest that additional plerixafor leads to increased stem cell collection in a shorter time. There was insufficient evidence to determine whether additional plerixafor affects survival or adverse events.The two trials included in the meta-analysis, both of which were conducted by the Genzyme Corporation, the manufacturer of plerixafor, were published several times. Two more RCTs examining the addition of plerixafor to a G-CSF mobilisation regimen terminated early without publishing any outcome. The trials included nine and five participants, respectively. Another RCT with 100 participants was recently completed, but has not yet published outcomes. Due to the unpublished RCTs, it is possible that our review is affected by publication bias, even though two trials failed to recruit a sufficient number of participants to analyse any data." @default.
• W1799863640 created "2016-06-24" @default.
• W1799863640 creator A5016126557 @default.
• W1799863640 creator A5041461263 @default.
• W1799863640 creator A5057387418 @default.
• W1799863640 creator A5084791226 @default.
• W1799863640 creator A5091567011 @default.
• W1799863640 date "2015-10-20" @default.
• W1799863640 modified "2023-10-16" @default.
• W1799863640 title "Additional plerixafor to granulocyte colony-stimulating factors for haematopoietic stem cell mobilisation for autologous transplantation in people with malignant lymphoma or multiple myeloma" @default.
• W1799863640 cites W1552370693 @default.
• W1799863640 cites W1575556154 @default.
• W1799863640 cites W1584180082 @default.
• W1799863640 cites W1737313009 @default.
• W1799863640 cites W1799863640 @default.
• W1799863640 cites W1955546858 @default.
• W1799863640 cites W1967008538 @default.
• W1799863640 cites W1978321902 @default.
• W1799863640 cites W1979346677 @default.
• W1799863640 cites W1994809546 @default.
• W1799863640 cites W1995712528 @default.
• W1799863640 cites W2000125803 @default.
• W1799863640 cites W2016969330 @default.
• W1799863640 cites W2020806642 @default.
• W1799863640 cites W2023512317 @default.
• W1799863640 cites W2034794564 @default.
• W1799863640 cites W2059900269 @default.
• W1799863640 cites W2072018052 @default.
• W1799863640 cites W2075642745 @default.
• W1799863640 cites W2078466049 @default.
• W1799863640 cites W2078566370 @default.
• W1799863640 cites W2083488386 @default.
• W1799863640 cites W2084084240 @default.
• W1799863640 cites W2085269642 @default.
• W1799863640 cites W2088095316 @default.
• W1799863640 cites W2089982195 @default.
• W1799863640 cites W2101995865 @default.
• W1799863640 cites W2111988435 @default.
• W1799863640 cites W2120950567 @default.
• W1799863640 cites W2121735943 @default.
• W1799863640 cites W2154615874 @default.
• W1799863640 cites W2156098321 @default.
• W1799863640 cites W2156425432 @default.
• W1799863640 cites W2160088903 @default.
• W1799863640 cites W2161817637 @default.
• W1799863640 cites W2163065691 @default.
• W1799863640 cites W2164441850 @default.
• W1799863640 cites W2468996569 @default.
• W1799863640 cites W2522321940 @default.
• W1799863640 cites W2568336425 @default.
• W1799863640 cites W2582541161 @default.
• W1799863640 cites W2585001660 @default.
• W1799863640 cites W2590800135 @default.
• W1799863640 cites W2979601463 @default.
• W1799863640 cites W2981107819 @default.
• W1799863640 cites W4211016085 @default.
• W1799863640 doi "https://doi.org/10.1002/14651858.cd010615.pub2" @default.
• W1799863640 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26484982" @default.
• W1799863640 hasPublicationYear "2015" @default.
• W1799863640 type Work @default.
• W1799863640 sameAs 1799863640 @default.
• W1799863640 citedByCount "10" @default.
• W1799863640 countsByYear W17998636402015 @default.
• W1799863640 countsByYear W17998636402016 @default.
• W1799863640 countsByYear W17998636402017 @default.
• W1799863640 countsByYear W17998636402018 @default.
• W1799863640 countsByYear W17998636402019 @default.
• W1799863640 crossrefType "journal-article" @default.
• W1799863640 hasAuthorship W1799863640A5016126557 @default.
• W1799863640 hasAuthorship W1799863640A5041461263 @default.
• W1799863640 hasAuthorship W1799863640A5057387418 @default.
• W1799863640 hasAuthorship W1799863640A5084791226 @default.
• W1799863640 hasAuthorship W1799863640A5091567011 @default.
• W1799863640 hasBestOaLocation W17998636402 @default.
• W1799863640 hasConcept C126322002 @default.
• W1799863640 hasConcept C129470790 @default.
• W1799863640 hasConcept C13373296 @default.
• W1799863640 hasConcept C143998085 @default.
• W1799863640 hasConcept C170493617 @default.
• W1799863640 hasConcept C194409129 @default.
• W1799863640 hasConcept C2776364478 @default.
• W1799863640 hasConcept C2776694085 @default.
• W1799863640 hasConcept C2777767877 @default.
• W1799863640 hasConcept C2778828106 @default.
• W1799863640 hasConcept C2779050716 @default.
• W1799863640 hasConcept C2779338263 @default.
• W1799863640 hasConcept C2911091166 @default.
• W1799863640 hasConcept C535046627 @default.
• W1799863640 hasConcept C71924100 @default.
• W1799863640 hasConceptScore W1799863640C126322002 @default.
• W1799863640 hasConceptScore W1799863640C129470790 @default.
• W1799863640 hasConceptScore W1799863640C13373296 @default.
• W1799863640 hasConceptScore W1799863640C143998085 @default.
• W1799863640 hasConceptScore W1799863640C170493617 @default.
• W1799863640 hasConceptScore W1799863640C194409129 @default.
• W1799863640 hasConceptScore W1799863640C2776364478 @default.
• W1799863640 hasConceptScore W1799863640C2776694085 @default.
• W1799863640 hasConceptScore W1799863640C2777767877 @default.
• W1799863640 hasConceptScore W1799863640C2778828106 @default.
• W1799863640 hasConceptScore W1799863640C2779050716 @default.

• next